| Treatment regiment |
Follow up period (months) |
Results |
Ref |
| *v-PDT |
12 |
VA improved (15 letters or more) in AMD and PCV by 6% and 25%, respectively. Fluorescein leakage was suppressed in 86% of PCV and 61% of AMD eyes, respectively. |
[153] |
| *v-PDT |
24 |
VA preserved or improved in 79% of eyes. Recurrence of polypoidal lesions in 64% of eyes. An abnormal branching vascular network persisted in all subjects. |
[72] |
| v-PDT |
19.2 |
Regression of the polypoidal lesions observed in 94% of eyes. The branching vascular network remained in all eyes. |
[154] |
| *v-PDT |
12 |
Significantly better response to v-PDT in terms of VA improvement and effect durability. |
[69] |
| **v-PDT |
12 |
Significantly lower v-PDT frequency and greater improvement in the visual acuity than AMD. |
[70] |
| *v-PDT |
12 |
The visual acuity improved in 56.3% of patients, remained the same in 31.3%, and decreased in 12.5% and. No patient had any long lasting complication after the treatment. |
[68] |
| *v-PDT |
36 |
75% of the treated eyes had no significant loss of vision, and 14.8% showed significant improvement in visual acuity. |
[65] |
| *v-PDT |
60 |
Mean VA letter score loss is similar between patients with AMD (-7.25) and with PCV (-5.36) at the month 60examination. Significantly more frequent retreatments in the years 3 and 4 than patients with AMD. |
[155] |
| *v-PDT+ranibizumab 0.5 mg |
12 |
Complete regression of polypoidal lesions in combination therapy group. |
[119] |
| *v-PDT+ranibizumab 0.5 mg |
12 |
The mean BCVA change from baseline was +12.3 letters. 58.3% of patients had a BCVA gain of 15 letters or more. All patients underwent regression of polyps without recurrence. |
[156] |
| *v-PDT+bevacizumab 1.25 mg |
12 |
Lower rate of post v-PDT hemorrhage. Recurrence rate was unchanged. |
[157] |
| ranibizumab 0.5 mg+*v-PDT |
12 |
Improved VA and reduced exudation. |
[158] |
| **v-PDT+ bevacizumab 1.25 mg |
12 |
Improved VA in 56% treated eyes. |
[73] |
*standard fluence: 50 J/cm